Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Kansas City Research Institute
mi
from
Kansas City, MO
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Kansas City Research Institute
mi
from
Kansas City, MO
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Binghamton Gastroenterology Associates, PC
mi
from
Binghamton, NY
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Binghamton Gastroenterology Associates, PC
mi
from
Binghamton, NY
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Asheville Gastroenterology Associates, P.A.
mi
from
Asheville, NC
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Asheville Gastroenterology Associates, P.A.
mi
from
Asheville, NC
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Carolinas Center For Liver Disease
mi
from
Statesville, NC
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Carolinas Center For Liver Disease
mi
from
Statesville, NC
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Lehigh Valley Health Network
mi
from
Allentown, PA
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Lehigh Valley Health Network
mi
from
Allentown, PA
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Quality Medical Research Pllc
mi
from
Nashville, TN
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Quality Medical Research Pllc
mi
from
Nashville, TN
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Mt Vernon Endoscopy Center
mi
from
Alexandria, VA
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Mt Vernon Endoscopy Center
mi
from
Alexandria, VA
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Digestive and Liver Disease Specialists
mi
from
Norfolk, VA
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Digestive and Liver Disease Specialists
mi
from
Norfolk, VA
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Orlando Immunology Center
mi
from
Orlando, FL
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Orlando Immunology Center
mi
from
Orlando, FL
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
University of Chicago
mi
from
Chicago, IL
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Indiana University Health
mi
from
Indianapolis, IN
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Indiana University Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Weill-Cornell Medical College
mi
from
New York, NY
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Duke Univ Med Ctr
mi
from
Durham, NC
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
University Hospitals at Case Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Advanced Liver Therapies
mi
from
Houston, TX
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Advanced Liver Therapies
mi
from
Houston, TX
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Texas Liver Institute
mi
from
San Antonio, TX
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Texas Liver Institute
mi
from
San Antonio, TX
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Inova Fairfax Hospital
mi
from
Falls Church, VA
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Inova Fairfax Hospital
mi
from
Falls Church, VA
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Dean Clinic
mi
from
Madison, WI
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Dean Clinic
mi
from
Madison, WI
Click here to add this to my saved trials
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Darlinghurst,
UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Darlinghurst,
Click here to add this to my saved trials
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/23/2015
Advanced Medical Research Center
mi
from
Port Orange, FL
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/23/2015
Advanced Medical Research Center
mi
from
Port Orange, FL
Click here to add this to my saved trials
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/23/2015
Florida Medical Clinic-Tampa Clinic
mi
from
Tampa, FL
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/23/2015
Florida Medical Clinic-Tampa Clinic
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/23/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/23/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/23/2015
Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/23/2015
Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/23/2015
Washington University School of Medicine
mi
from
St. Louis, MO
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/23/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/23/2015
Mount Sinai School of Medicine
mi
from
New York, NY
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/23/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/23/2015
Dayton Science Institute
mi
from
Dayton, OH
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/23/2015
Dayton Science Institute
mi
from
Dayton, OH
Click here to add this to my saved trials
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated:  9/23/2015
mi
from
Abbotsford,
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis
A Phase 2, Multi-dose, Double-blind, Placebo-controlled, Randomized, Multicenter Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Subjects With Active Ulcerative Colitis
Status: Enrolling
Updated: 9/23/2015
mi
from
Abbotsford,
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
ACMG Endoscopy Center
mi
from
Anaheim, CA
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
ACMG Endoscopy Center
mi
from
Anaheim, CA
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
ACRI - Phase I
mi
from
Anaheim, CA
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
ACRI - Phase I
mi
from
Anaheim, CA
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Advanced Clinical Research Institute - Phase 1, LLC
mi
from
Anaheim, CA
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Advanced Clinical Research Institute - Phase 1, LLC
mi
from
Anaheim, CA
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
West Coast Clinical Trials, LLC
mi
from
Cypress, CA
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
West Coast Clinical Trials, LLC
mi
from
Cypress, CA
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Alliance Clinical Research
mi
from
Oceanside, CA
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Alliance Clinical Research
mi
from
Oceanside, CA
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Clinical Research of the Rockies
mi
from
LaFayette, CO
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Clinical Research of the Rockies
mi
from
LaFayette, CO
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Clinical Research of West Florida
mi
from
Clearwater, FL
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Clinical Research of West Florida
mi
from
Clearwater, FL
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Gasteroenterology Consultants of Clearwater
mi
from
Clearwater, FL
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Gasteroenterology Consultants of Clearwater
mi
from
Clearwater, FL
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
West Coast Endoscopy Center
mi
from
Clearwater, FL
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
West Coast Endoscopy Center
mi
from
Clearwater, FL
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Shands Endoscopy Center
mi
from
Gainesville, FL
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Shands Endoscopy Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Shands Hospital at the University of Florida
mi
from
Gainesville, FL
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Shands Hospital at the University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Shands Medical Plaza and Cancer Center
mi
from
Gainesville, FL
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Shands Medical Plaza and Cancer Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
University of Florida - College of Medicine
mi
from
Gainsville, FL
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
University of Florida - College of Medicine
mi
from
Gainsville, FL
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Gastroenterology Group of Naples
mi
from
Naples, FL
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Gastroenterology Group of Naples
mi
from
Naples, FL
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
North Florida Gastroenterology Research, LLC
mi
from
Orange Park, FL
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
North Florida Gastroenterology Research, LLC
mi
from
Orange Park, FL
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Internal Medicine Specialists
mi
from
Orlando, FL
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Internal Medicine Specialists
mi
from
Orlando, FL
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Gastroenterology Associates of Central Georgia
mi
from
Macon, GA
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Gastroenterology Associates of Central Georgia
mi
from
Macon, GA
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Cotton-O'Neil Clinical Research Center, Digestive Health
mi
from
Topeka, KA
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Cotton-O'Neil Clinical Research Center, Digestive Health
mi
from
Topeka, KA
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Chevy Chase Endoscopy Center
mi
from
Chevy Chase, MD
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Chevy Chase Endoscopy Center
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Metropolitan Gastroenterology Group, P.C.
mi
from
Chevy Chase, MD
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Metropolitan Gastroenterology Group, P.C.
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Center for Digestive Health
mi
from
Troy, MI
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Center for Digestive Health
mi
from
Troy, MI
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Surgical Centers of Michigan
mi
from
Troy, MI
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Surgical Centers of Michigan
mi
from
Troy, MI
Click here to add this to my saved trials
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated:  9/24/2015
Nyu Langone Long Island Clinical Research Associates
mi
from
Great Neck, NY
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Study To Investigate The Safety And Efficacy Of Cp-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
Status: Enrolling
Updated: 9/24/2015
Nyu Langone Long Island Clinical Research Associates
mi
from
Great Neck, NY
Click here to add this to my saved trials